NS 11821

Drug Profile

NS 11821

Alternative Names: NS11821

Latest Information Update: 10 Mar 2017

Price : $50

At a glance

  • Originator NeuroSearch
  • Class Anxiolytics
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anxiety disorders; CNS disorders

Most Recent Events

  • 08 Mar 2017 Discontinued - Phase-I for Anxiety disorders in Denmark (PO) before March 2017 (NeuroSearch website, March 2017) (NeuroSearch email communication, March 2017)
  • 08 Mar 2017 Discontinued - Phase-I for CNS disorders in Denmark (PO) before March 2017 (NeuroSearch website, March 2017) (NeuroSearch email communication, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top